Clinical validation would further added the credibility of this study and future studies with clinical data are encouraged to further validate the association of CDR2L, SPRED1, PFKP, ENG, KLF2, FSCN1 and VCAN with prognosis, chemotherapy and immunotherapy response of HCC patients. Here, CDR2L is linked to hepatocellular carcinoma.